Geneva, Switzerland (PRWEB) February 07, 2013
Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that the Company’s co-founder will present data on the Company’s core technology at the Cell Line Development and Engineering 2013 conference being held February 11 – 15 in Vienna, Austria. Selexis’ co-founder and scientific advisory board member, Nicolas Mermod, PhD, Professor of Biotechnology at Faculty of Biology and Medicine of the University of Lausanne, will present, “Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression,” on Friday, February 15 at 1:45 PM as part of the CHO Cell Engineering tract.
“Omics-based approaches of CHO cell engineering and clone characterisation for improved protein expression”
Incorporation of epigenetic regulatory DNA elements to prevent silencing can yield high and stable expression from CHO cells with a high frequency. We determined the sequence of a CHO genome used for pharmaceutical production and of derived therapeutic producing clones and allowed the characterisation of the alterations of the genomic and transgene sequence of candidate cell lines. This presentation will illustrate how a systematic and multi-level ‘Omics’ approach may be used to improve the expression of pharmaceutical proteins.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexi
Copyright©2012 Vocus, Inc.
All rights reserved